A Forensic Guide: Using Extreme Value Theory (EVT) to Find Weaknesses in Pharma and Biotech Pitch Decks
When a venture capital (VC) firm or a legal team evaluates an early-stage biotech or pharma startup, due diligence is
The LinkedIn Humblebrag: A Study in Digital Narcissism
LinkedIn. The once-practical platform for professional networking has evolved into a peculiar blend of motivational seminar, humblebrag arena, and corporate
The Graveyard of Innovation: Pharma’s Survivorship Bias
I have a confession to make: I’m fascinated by failure. Not in a morbid, schadenfreude sort of way, but
Mentoring: A Marathon, Not a Shortcut
Mentoring: It’s Not Just a LinkedIn Title
Mentoring is having a moment. If you’ve scrolled through LinkedIn recently,
Overall Survival: The Gold Standard Under Scrutiny
Overall survival (OS) has long been considered the gold standard in oncology trials. Defined as the time from treatment initiation
PPAS as a solution?
Probability of Pricing and Access Success (PPAS) is an emerging metric that evaluates the likelihood of a drug achieving favorable
The problem of PTS
Probability of Technical Success (PTS) is a metric that evaluates the likelihood that a drug candidate will successfully navigate clinical
Fun with Funds: Exploring the MSCI World Pharmaceuticals, Biotechnology, and Life Sciences Index
The MSCI World Pharmaceuticals, Biotechnology, and Life Sciences Index (USD) is a key benchmark for the biotech and pharmaceutical industry.
The Art of Not Killing a Project: Navigating the Fine Line Between Risk and Reward
Killing a project is easy. There’s a laundry list of reasons why something “shouldn’t move forward”: it’s
Ex-Factor: Why Everyone Loves to Advertise Their Exes (and Why It’s Mostly Nonsense)
LinkedIn profiles boasting titles like ex-McKinsey, ex-Bain, ex-Novartis, or ex-Roche. It’s as if these professionals are collecting exes, not in their personal lives (well, hopefully), but in their résumés, brandishing them like badges of honor.
